GBT:EPA
Guerbet SA
€9.95
arrow_downward
-1.49%(-0.15) 1D
Apr 21, 5:35:16 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GBT...
Open
€10.14
High
€10.14
Low
€9.86
Mkt. cap
138.96M
Avg. vol.
22.80K
Volume
3.52K
52-wk high
€23.70
52-wk low
€8.01
EPS
-€8.57
Shares outstanding
12.64M
No. of employees
3K
News stories
From sources across the web
Yahoo Finance
·
17 minutes ago
Weatherford (NASDAQ:WFRD) Posts Better-Than-Expected Sales In Q1 CY2026
Business Wire
·
18 minutes ago
908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Profile
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories.
An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
About Guerbet SA
AI content may include mistakes. Learn more